Pirow Bekker This is Me

Education

 View all 6 references Web References

1. 1. www.ibdnews.com

   www.ibdnews.com/2007/05/clear- - [Cached]

   Published on: 5/23/2007   Last Visited: 7/10/2007

   Patients with active disease reported significant improvement in their condition when treated with Traficet-EN compared to those in the control group," said Pirow Bekker, M.D., Ph.D., Vice President, Medical and Clinical Affairs of ChemoCentryx, Inc.

2. 2. ChemoCentryx - News - Press Releases

   www.chemocentryx.com/news/2006 - [Cached]

   Published on: 12/1/2006   Last Visited: 12/20/2007

   The clinical analysis of inflammatory response data will be presented by Pirow Bekker, M.D., Ph.D., ChemoCentryx's Vice President, Medical and Clinical Affairs, as part of Session VIII: Original basic and clinical research abstract presentations on Sunday, December 3, 2006 at 11:10 a.m. Eastern Standard Time in a presentation entitled "Traficet-EN (CCX282), an Orally Active Inhibitor of Chemokine Receptor CCR9 for Treatment of Crohn's Disease."
   
   "In designing our four-week Phase 2 trial of this first-in-class compound, we sought to initially evaluate safety and tolerability when administering Traficet-EN to subjects with Crohn's disease. We are encouraged by the consistent evidence achieved in our early Phase 2 trial showing that Traficet-EN appears to reduce the inflammatory response in the digestive tract and to alleviate the symptoms of Crohn's disease among patients," said Dr. Bekker.

3. 3. ChemoCentryx - News - Press Releases

   www.chemocentryx.com/news/2006 - [Cached]

   Published on: 10/24/2006   Last Visited: 12/20/2007

   "In addition to being very pleased with the safety profile observed to date, we are very encouraged by the percentage of patients who received clinical benefit from Traficet-EN as observed by a significant drop in their CDAI scores and CRP levels," said Pirow Bekker, M.D., Ph.D., ChemoCentryx's Vice President, Medical and Clinical Affairs.